These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23984227)

  • 1. Hit hard and early: Can the march of psoriasis be halted?
    Jandhyala S
    Indian Dermatol Online J; 2013 Jul; 4(3):177-9. PubMed ID: 23984227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis.
    Fisher VS
    J Manag Care Pharm; 2005; 11(1):33-55. PubMed ID: 15667232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(27):1-66. PubMed ID: 23074532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of psoriasis as a systemic disease: what is the evidence?
    Korman NJ
    Br J Dermatol; 2020 Apr; 182(4):840-848. PubMed ID: 31225638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents.
    Kaushik SB; Lebwohl MG
    J Am Acad Dermatol; 2019 Jan; 80(1):27-40. PubMed ID: 30017705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis comorbidities.
    Guenther L; Gulliver W
    J Cutan Med Surg; 2009; 13 Suppl 2():S77-87. PubMed ID: 19799830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis.
    Abramovits W; Schlessinger J
    J Drugs Dermatol; 2020 Mar; 19(3):306-313. PubMed ID: 32550687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.
    Armstrong AW; Brezinski EA; Follansbee MR; Armstrong EJ
    Curr Pharm Des; 2014; 20(4):500-12. PubMed ID: 23565631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic abnormalities of psoriatic patients: a retrospective study.
    Yin L; Xu JL; Hu YY; Johnston A; Yin ZQ
    Clin Cosmet Investig Dermatol; 2016; 9():443-449. PubMed ID: 27877062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic.
    Woo YR; Park CJ; Kang H; Kim JE
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Secukinumab Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report.
    Kostaki D; Aquila E; Macaluso L; Mattozzi C; Richetta AG
    Case Rep Dermatol; 2019; 11(Suppl 1):17-22. PubMed ID: 31662734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections.
    Kaushik SB; Lebwohl MG
    J Am Acad Dermatol; 2019 Jan; 80(1):43-53. PubMed ID: 30017706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managed care aspects of psoriasis and psoriatic arthritis.
    Evans C
    Am J Manag Care; 2016 Jun; 22(8 Suppl):s238-43. PubMed ID: 27356195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities.
    Gisondi P; Bellinato F; Girolomoni G; Albanesi C
    Front Pharmacol; 2020; 11():117. PubMed ID: 32161545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP).
    Tveit KS; Duvetorp A; Østergaard M; Skov L; Danielsen K; Iversen L; Seifert O
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):340-354. PubMed ID: 30242921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective.
    Johar A; Thevarajah S; Heng A; Chan LC; Ch'ng CC; Mohd Safdar NA; Muniandy P; Taib T; Tan WC; Tey KE
    Dermatol Res Pract; 2019; 2019():8923168. PubMed ID: 31214257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives.
    Kapniari E; Papadimitriou P; Dalamaga M; Makavos G; Piaserico S; Egeberg A; Ikonomidis I; Papadavid E
    Curr Vasc Pharmacol; 2020; 18(6):592-609. PubMed ID: 32445456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Inflammatory skin march" in atopic dermatitis and psoriasis.
    Furue M; Kadono T
    Inflamm Res; 2017 Oct; 66(10):833-842. PubMed ID: 28620798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary management of moderate to severe plaque psoriasis.
    Wu JJ
    Am J Manag Care; 2017 Dec; 23(21 Suppl):S403-S416. PubMed ID: 29297664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.